PubRank

Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.

PubWeight™: 0.87‹?›

🔗 View Article (PMID 24947287)

Published in Stroke on June 19, 2014

Authors

Robert P Giugliano1, Christian T Ruff2, Natalia S Rost2, Scott Silverman2, Stephen D Wiviott2, Cheryl Lowe2, Naveen Deenadayalu2, Sabina A Murphy2, Laura T Grip2, Joshua M Betcher2, Anil Duggal2, Jay Dave2, Minggao Shi2, Michele Mercuri2, Elliott M Antman2, Eugene Braunwald2, ENGAGE AF-TIMI 48 Investigators

Author Affiliations

1: From the Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (R.P.G., C.T.R., S.D.W., C.L., N.D., S.A.M., L.T.G., E.M.A., E.B.); Department of Neurology, Massachusetts General Hospital, Boston (N.S.R., S.S.); Biostatistics, Quintiles, Inc, Durham, NC (J.M.B.); and Daiichi Sankyo, Inc, Pharma Development, Edison, NJ (A.D., J.D., M.S., M.M.). rgiugliano@partners.org.
2: From the Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (R.P.G., C.T.R., S.D.W., C.L., N.D., S.A.M., L.T.G., E.M.A., E.B.); Department of Neurology, Massachusetts General Hospital, Boston (N.S.R., S.S.); Biostatistics, Quintiles, Inc, Durham, NC (J.M.B.); and Daiichi Sankyo, Inc, Pharma Development, Edison, NJ (A.D., J.D., M.S., M.M.).

Associated clinical trials:

Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation (EngageAFTIMI48) | NCT00781391

Articles citing this ↘

Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation: Meta-Analysis. Stroke (2015) 0.88

Managing atrial fibrillation in the very elderly patient: challenges and solutions. Vasc Health Risk Manag (2015) 0.77

Practical and clinical considerations in assessing patients with atrial fibrillation for switching to non-vitamin K antagonist oral anticoagulants in primary care. Int J Gen Med (2015) 0.76

An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation. Core Evid (2015) 0.75

Non-Vitamin K Antagonist Oral Anticoagulants: New Choices for Patient Management in Atrial Fibrillation. Am J Cardiovasc Drugs (2015) 0.75

Edoxaban. Hosp Pharm (2015) 0.75

Stability of High-Quality Warfarin Anticoagulation in a Community-Based Atrial Fibrillation Cohort: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. J Am Heart Assoc (2016) 0.75

Articles by these authors ⇆

Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70

Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. Circulation (2017) 0.75

Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). Stroke (2016) 0.75

Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). Circ Arrhythm Electrophysiol (2017) 0.75

Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48. Clin Cardiol (2016) 0.75